American Century Companies Inc. Acquires 319,634 Shares of Biohaven Ltd. (NYSE:BHVN)

American Century Companies Inc. increased its holdings in shares of Biohaven Ltd. (NYSE:BHVN) by 166.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 511,237 shares of the company’s stock after purchasing an additional 319,634 shares during the quarter. American Century Companies Inc. owned 0.58% of Biohaven worth $17,745,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. Perceptive Advisors LLC lifted its holdings in shares of Biohaven by 129.4% during the 4th quarter. Perceptive Advisors LLC now owns 1,725,047 shares of the company’s stock valued at $73,832,000 after buying an additional 973,227 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Biohaven by 20.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 518,904 shares of the company’s stock worth $22,209,000 after acquiring an additional 86,890 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Biohaven by 280.5% during the 1st quarter. Vanguard Group Inc. now owns 6,308,853 shares of the company’s stock valued at $345,031,000 after acquiring an additional 4,650,702 shares during the period. CWM LLC increased its stake in shares of Biohaven by 1,893.4% in the 2nd quarter. CWM LLC now owns 14,552 shares of the company’s stock worth $505,000 after purchasing an additional 13,822 shares in the last quarter. Finally, Oak Ridge Investments LLC raised its holdings in Biohaven by 197.6% in the 2nd quarter. Oak Ridge Investments LLC now owns 22,000 shares of the company’s stock worth $764,000 after purchasing an additional 14,607 shares during the period. 88.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on BHVN. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a report on Monday, August 19th. Royal Bank of Canada reissued an “outperform” rating and issued a $59.00 target price on shares of Biohaven in a report on Wednesday, September 4th. UBS Group lowered their price target on shares of Biohaven from $55.00 to $54.00 and set a “buy” rating on the stock in a report on Tuesday, August 13th. Jefferies Financial Group assumed coverage on shares of Biohaven in a research note on Monday, September 16th. They issued a “buy” rating and a $57.00 price objective for the company. Finally, William Blair upgraded shares of Biohaven to a “strong-buy” rating in a research note on Friday, August 30th. Eleven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Biohaven currently has a consensus rating of “Buy” and a consensus target price of $54.70.

Insider Transactions at Biohaven

In other Biohaven news, Director John W. Childs purchased 28,400 shares of the stock in a transaction that occurred on Thursday, July 18th. The stock was purchased at an average price of $35.67 per share, with a total value of $1,013,028.00. Following the acquisition, the director now owns 2,339,741 shares in the company, valued at $83,458,561.47. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 16.00% of the company’s stock.

Biohaven Stock Down 0.1 %

Shares of Biohaven stock opened at $40.39 on Friday. Biohaven Ltd. has a twelve month low of $16.45 and a twelve month high of $62.21. The business has a 50-day moving average price of $38.31 and a 200-day moving average price of $41.18. The firm has a market cap of $3.57 billion, a price-to-earnings ratio of -5.91 and a beta of 1.30.

Biohaven (NYSE:BHVN) last released its quarterly earnings data on Thursday, August 8th. The company reported ($3.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.72) by ($1.92). On average, equities analysts expect that Biohaven Ltd. will post -8.92 EPS for the current fiscal year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.